NCT01775956

Brief Summary

Septic shock remains the dominant cause of death in ICU's of the developed world with approximately 400,000 cases annually in the US and another 20,000 annually in Canada. While many retrospective and prospective reviews of septic shock patients have been undertaken worldwide, many key questions remain unanswered. These questions include the true incidence, associated morbidity and mortality of septic shock in North America, key factors associated with successful management and markers suggesting a high probability of a complicated clinical course. Part of the reason for the persistence of these questions, is the fact that previous and ongoing reviews of septic shock and severe sepsis have been either limited in number (typically \<150) or biased by the need to be eligible for specific clinical trials (typically, non-eligible patients have not been followed and had data collected. We propose to examine specific questions within a temporally comprehensive cohort of septic shock patients by review of individual charts using a defined data-extraction template.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
10,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Dec 2003

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2003

Completed
9.1 years until next milestone

First Submitted

Initial submission to the registry

January 16, 2013

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 25, 2013

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2018

Completed
Last Updated

July 25, 2013

Status Verified

July 1, 2013

Enrollment Period

14.1 years

First QC Date

January 16, 2013

Last Update Submit

July 24, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Outcome as determined by treatment choices

    Analysis will be used to examine critical therapeutic elements of outcome (choice of antibiotics, rapidity of initiation, use of multiple drug combinations, choice and speed of initiation of pressors, choice and degree of fluid resuscitation, etc). Preliminary analysis of data from 2800 charts suggests an annual incidence of incidence of septic shock in North America (without adjustment for age, sex or socioeconomic status) of approximately 175,000 annual cases, a lower number than has been suggested in some other studies. Further preliminary analysis suggests there is a critical relationship between rapidity of antibiotic initiation and source control implementation following onset of hypotension and outcome in septic shock (Kumar et al, CCM 2006).

    Participants will be followed for the Average length of hospital stay 4-5 weeks

Secondary Outcomes (2)

  • Vasopressor use as a predictor of complications

    Participants will be followed for the Average length of hospital stay 4-5 weeks

  • Elements that predict complications in ICU

    Participants will be followed for the Average length of hospital stay 4-5 weeks

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Medical charts from all patients coded as septic shock in an internal ICU registry since 1994.

You may qualify if:

  • The primary analysis will include all patients admitted to the institution with a final diagnosis of septic shock (including transfers).

You may not qualify if:

  • ICU patients who do not have a diagnosis of septic shock

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Health Sciences Centre, Winnipeg

Winnipeg, Manitoba, R3A 1R9, Canada

RECRUITING

MeSH Terms

Conditions

Shock, Septic

Condition Hierarchy (Ancestors)

SepsisInfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and SymptomsShock

Study Officials

  • Anand Kumar, MD

    University of Manitoba

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Anand Kumar, MD

CONTACT

Wendy Janz, RN

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

January 16, 2013

First Posted

January 25, 2013

Study Start

December 1, 2003

Primary Completion

January 1, 2018

Study Completion

July 1, 2018

Last Updated

July 25, 2013

Record last verified: 2013-07

Locations